Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 33, 2009, Pages 13820-13825

  Creighton, Chad J ^a   Li, Xiaoxian ^a   Landis, Melissa ^a   Dixon, J Michael ^b   Neumeister, Veronique M ^c   Sjolund, Ashley ^c   Rimm, David L ^c   Wong, Helen ^a   Rodriguez, Angel ^a   Herschkowitz, Jason I ^a   Fan, Cheng ^d   Zhang, Xiaomei ^a   He, Xiaping ^c   Pavlick, Anne ^a   Gutierrez, M Carolina ^a   Renshaw, Lorna ^b   Larionov, Alexey A ^b   Faratian, Dana ^b   Hilsenbeck, Susan G ^a   Perou, Charles M ^d   Lewis, Michael T ^a   Rosen, Jeffrey M ^a   Chang, Jenny C ^a,e   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e BCM 600 ^*  (United States)

Author keywords

CD44+ CD24 low markers; Gene expression signature; Mesenchymal features; Treatment resistance; Tumor initiating cancer cells

Indexed keywords

CD24 ANTIGEN; CLAUDIN; CYTOKERATIN; DOCETAXEL; GELATINASE A; HERMES ANTIGEN; LETROZOLE; VIMENTIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL LINEAGE; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MESENCHYME; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD24; ANTIGENS, CD44; BIOPSY; BREAST NEOPLASMS; CELL MEMBRANE; EPITHELIUM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MESODERM; MODELS, BIOLOGICAL; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 69549131213     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0905718106     Document Type: Article

References (31)

1. Dick JE (2008) Stem cell concepts renew cancer research. Blood 112:4793-4807.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988. (Pubitemid 36418143)
3. Li X, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672-679.
4. Sorlie T, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874. (Pubitemid 32878711)
5. PerouCM,et al. (2000) Molecular portraits ofhumanbreast tumours. Nature 406:747-752.
6. Herschkowitz JI, et al. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8:R76.
7. Andarawewa KL, et al. (2007) Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer Res 67:8662-8670.
8. Buijs JT, et al. (2007) Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67:8742-8751. (Pubitemid 47437450)
9. Damonte P, Gregg JP, Borowsky AD, Keister BA, Cardiff RD (2007) EMT tumorigenesis in the mouse mammary gland. Lab Invest 87:1218-1226. (Pubitemid 350126707)
10. Guarino M, Rubino B, Ballabio G (2007) The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39:305-318. (Pubitemid 46897605)
11. Kokkinos MI, et al. (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 185:191-203. (Pubitemid 46957486)
12. Lo HW, et al. (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67:9066-9076.
13. Tiezzi DG, Fernandez SV, Russo J (2007) Epithelial mesenchymal transition during the neoplastic transformation of human breast epithelial cells by estrogen. Int J Oncol 31:823-827.
14. Trimboli AJ, et al. (2008) Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 68:937-945. (Pubitemid 351206773)
15. Yang AD, et al. (2006) Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12:4147-4153.
16. Kajiyama H, et al. (2006) Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary. Oncology 71:394-401. (Pubitemid 47573703)
17. Kajiyama H, et al. (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31:277-283.
18. Hennessy BT, et al. (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69:4116-4124.
19. Sarrio D, et al. (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989-997. (Pubitemid 351272216)
20. Mani SA, et al. (2007) Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 104:10069-10074.
21. Mani SA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715. (Pubitemid 351636299)
22. Hiscox S, et al. (2006) Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 118:290-301. (Pubitemid 41779067)
23. GotteM,YipGW(2006) Heparanase, hyaluronan,andCD44in cancers:Abreast carcinoma perspective. Cancer Res 66:10233-10237.
24. ChangJC, et al. (2005) Patterns of resistanceandincomplete response to docetaxelbygene expression profiling in breast cancer patients. J Clin Oncol 23:1169-1177. (Pubitemid 46202273)
25. ChangJC, et al. (2003)Geneexpression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369. (Pubitemid 36957839)
26. Miller WR, et al. (2007) Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics 17:813-826. (Pubitemid 47462295)
27. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168. (Pubitemid 28144151)
28. Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8:1323-1327. (Pubitemid 35373567)
29. Creighton CJ, et al. (2008) Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26:4078-4085.
30. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550. (Pubitemid 41528093)
31. Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial- mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 172:973-981.